Seeking Alpha

Steve Rosenman's  Instablog

Steve Rosenman
Send Message
Mr. Rosenman has nearly 15-years executive experience in the health and wellness sectors, including weight loss, cosmetics skincare and nutrition, both Rx and OTC. Expertise areas include strategic market and product planning and corporate development (evaluation, recommendation and execution of... More
  • Important Patent Score For Amarin 11 comments
    Mar 27, 2013 12:30 PM | about stocks: AMRN

    Patent 13/417,899 - for Vascepa to be used in conjunction with Lipitor was given notice of allowance (NYSE:NOA). This is an important step in protecting the compound in use with popular statins, and vital to keep PFE in the game for a premium.

    Maintain view of BO, $28-32 PT. Also see corresponding insta-blog post on scripts topic today.

    Themes: PFE Stocks: AMRN
Back To Steve Rosenman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (11)
Track new comments
  • Jolk
    , contributor
    Comments (220) | Send Message
     
    It has Reasons for Allowance, still great news, but Notice of Allowance should soon follow.
    27 Mar 2013, 12:52 PM Reply Like
  • bravo33
    , contributor
    Comments (60) | Send Message
     
    Jolk, what's normal timing between Reason for Allowance and Notice of Allowance? Thx.
    27 Mar 2013, 02:13 PM Reply Like
  • Jolk
    , contributor
    Comments (220) | Send Message
     
    It varies, 520 took 2 months, I'd guess 45-75 days
    27 Mar 2013, 11:00 PM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » Jolk is correct, generally 1-2 months.
    27 Mar 2013, 11:10 PM Reply Like
  • amrnBagHolder
    , contributor
    Comments (73) | Send Message
     
    Not sure who to believe in the internet news/media/hype/bash publishing world. I can say after the AF eyeball story - he went a little too far and lost any once of credibility he had with me. I like hearing opposing opinions and such, but this article/headline was incredibly stupid and obviously meant to twist SRs comments and hurt his credibility. Steve, you are still a little to optimistic for me, but continue to post your views as they do cheer me up. Just don't stoop down to AFs level. Please keep your articles professional.... Thanks in advance and looking forward to your next article.
    28 Mar 2013, 09:23 AM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » Fair enough, thanks. Do keep in mind, I'm not in the media/publishing business... My interest in AMRN started on the academic and scientific side when I wrote a thesis used at the University level for nutritional ingredients crossing over into Rx.
    28 Mar 2013, 09:38 AM Reply Like
  • DNDNLONG
    , contributor
    Comments (116) | Send Message
     
    My question for Adam is why does he only report things that he can twist as bad news. For example did he tweet or put out an article on the patents or the tier 2 development? One of his 15 predictions for 2013 was that AMRN will delay launch till Q2 which was proven false 2 week later as AMRN announced launching in 2 weeks. Then Adam out out some article that mgmt delayed launch hopes of a buyout which was a pure lie as they always said q1. His agenda is obvious. He has a hatred and vendetta against amrn, amrn mgmt and shareholders. It seems he puts out an article every time amrn is down 3% on some hogwash reason. So where are all the positive articles after all amrn traded as lows as 6.77 now at 7.60 or so. So where are the articles saying AMRN up on patents news or whatever.
    28 Mar 2013, 11:01 AM Reply Like
  • golfstud
    , contributor
    Comments (54) | Send Message
     
    I have followed amarin for a few years now and own a significant amount of shares and am long on the stock and company. I do agree with alot of what Steve says and think that this company could be well worth $30 plus after anchor is approved. Here is my question for Steve or anyone else that may want to reply, if the market for marine is worth $1.7 billion or $15 a share and anchor is 10 times the market shouldnt a buyout be signficantly higher by BP if and when Amarin gets anchor?
    28 Mar 2013, 06:30 PM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » Your assertion makes a lot of sense and with good launch of anchor could be justified...but lord only knows what AF would say if we dared suggest $40+
    28 Mar 2013, 08:58 PM Reply Like
  • bravo33
    , contributor
    Comments (60) | Send Message
     
    It's pretty clear, Steve, from AF's last 'sticky wicket' that he's operating on the fringe, apparently off his medication and neither WS nor investors any longer react to what he writes. He has self-destructed. Smart investors read conflicting views and I'll continue to read AF - I just won't invest my hard-earned money based on him.
    30 Mar 2013, 08:04 AM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » agree, he has rendered himself irrelevant.
    30 Mar 2013, 09:56 AM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.